Profile of ocriplasmin and its potential in the treatment of vitreomacular adhesion

Francisco R Stefanini,1–3 Maurício Maia,1 Paulo Falabella,1–3 Marcel Pfister,2,3 Moritz Niemeyer,2 Amir H Kashani,3 Mark S Humayun,3 Michael J Koss2,3,41Retina Division, Department of Ophthalmology and Visual Sciences, Federal University of Sao Paulo, Sao Paulo, Brazi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Stefanini FR, Maia M, Falabella P, Pfister M, Niemeyer M, Kashani AH, Humayun MS, Koss MJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/ad39e17d92fb45198ed107c387ba6ae9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ad39e17d92fb45198ed107c387ba6ae9
record_format	dspace
spelling	oai:doaj.org-article:ad39e17d92fb45198ed107c387ba6ae92021-12-02T07:25:50ZProfile of ocriplasmin and its potential in the treatment of vitreomacular adhesion1177-5483https://doaj.org/article/ad39e17d92fb45198ed107c387ba6ae92014-05-01T00:00:00Zhttp://www.dovepress.com/profile-of-ocriplasmin-and-its-potential-in-the-treatment-of-vitreomac-a16680https://doaj.org/toc/1177-5483 Francisco R Stefanini,1–3 Maurício Maia,1 Paulo Falabella,1–3 Marcel Pfister,2,3 Moritz Niemeyer,2 Amir H Kashani,3 Mark S Humayun,3 Michael J Koss2,3,41Retina Division, Department of Ophthalmology and Visual Sciences, Federal University of Sao Paulo, Sao Paulo, Brazil; 2Doheny Eye Institute, Los Angeles, CA, USA; 3Department of Ophthalmology, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA; 4Department of Ophthalmology, Goethe University, Frankfurt/Main, GermanyAbstract: The recent approval by the US Food and Drug Administration of ocriplasmin for the treatment of symptomatic vitreomacular adhesion (VMA), often associated with vitreomacular traction (VMT) and macular hole (MH), has brought new attention to the field of pharmacologic vitreolysis. The need for an enzyme to split the vitreomacular interface, which is formed by a strong adhesive interaction between the posterior vitreous cortex and the internal limiting membrane, historically stems from pediatric eye surgery. This review summarizes the different anatomic classifications of posterior vitreous detachment or anomalous posterior vitreous detachment and puts these in the context of clinical pathologies commonly observed in clinical practice of the vitreoretinal specialist, such as MH, VMT, age-related macular degeneration, and diabetic macular edema. We revisit the outcome of the Phase II studies that indicated ocriplasmin was a safe and effective treatment for selected cases of symptomatic VMA and MH. Release of VMA at day 28 was achieved by 26.5% of patients in the ocriplasmin group versus 10.1% in the placebo group (P<0.001). Interestingly, for MHs, the numbers were more remarkable. Predictive factors for successful ocriplasmin treatment were identified for VMT (VMA diameter smaller than 1,500 µm) and MH (smaller than 250 µm). In comparison with the highly predictable outcome after vitrectomy, the general success rate of ocriplasmin not under clinical trial conditions has not fully met expectations and needs to be proven in real-world clinical settings. The ocriplasmin data will be compared in the future with observational data on spontaneous VMA release, will help retina specialists make more accurate predictions, and will improve outcome rates.Keywords: ocriplasmin, microplasmin, posterior vitreous detachment, vitreomacular traction, macular hole, pharmacologic vitreolysisStefanini FRMaia MFalabella PPfister MNiemeyer MKashani AHHumayun MSKoss MJDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2014, Iss default, Pp 847-856 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Stefanini FR Maia M Falabella P Pfister M Niemeyer M Kashani AH Humayun MS Koss MJ Profile of ocriplasmin and its potential in the treatment of vitreomacular adhesion
description	Francisco R Stefanini,1–3 Maurício Maia,1 Paulo Falabella,1–3 Marcel Pfister,2,3 Moritz Niemeyer,2 Amir H Kashani,3 Mark S Humayun,3 Michael J Koss2,3,41Retina Division, Department of Ophthalmology and Visual Sciences, Federal University of Sao Paulo, Sao Paulo, Brazil; 2Doheny Eye Institute, Los Angeles, CA, USA; 3Department of Ophthalmology, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA; 4Department of Ophthalmology, Goethe University, Frankfurt/Main, GermanyAbstract: The recent approval by the US Food and Drug Administration of ocriplasmin for the treatment of symptomatic vitreomacular adhesion (VMA), often associated with vitreomacular traction (VMT) and macular hole (MH), has brought new attention to the field of pharmacologic vitreolysis. The need for an enzyme to split the vitreomacular interface, which is formed by a strong adhesive interaction between the posterior vitreous cortex and the internal limiting membrane, historically stems from pediatric eye surgery. This review summarizes the different anatomic classifications of posterior vitreous detachment or anomalous posterior vitreous detachment and puts these in the context of clinical pathologies commonly observed in clinical practice of the vitreoretinal specialist, such as MH, VMT, age-related macular degeneration, and diabetic macular edema. We revisit the outcome of the Phase II studies that indicated ocriplasmin was a safe and effective treatment for selected cases of symptomatic VMA and MH. Release of VMA at day 28 was achieved by 26.5% of patients in the ocriplasmin group versus 10.1% in the placebo group (P<0.001). Interestingly, for MHs, the numbers were more remarkable. Predictive factors for successful ocriplasmin treatment were identified for VMT (VMA diameter smaller than 1,500 µm) and MH (smaller than 250 µm). In comparison with the highly predictable outcome after vitrectomy, the general success rate of ocriplasmin not under clinical trial conditions has not fully met expectations and needs to be proven in real-world clinical settings. The ocriplasmin data will be compared in the future with observational data on spontaneous VMA release, will help retina specialists make more accurate predictions, and will improve outcome rates.Keywords: ocriplasmin, microplasmin, posterior vitreous detachment, vitreomacular traction, macular hole, pharmacologic vitreolysis
format	article
author	Stefanini FR Maia M Falabella P Pfister M Niemeyer M Kashani AH Humayun MS Koss MJ
author_facet	Stefanini FR Maia M Falabella P Pfister M Niemeyer M Kashani AH Humayun MS Koss MJ
author_sort	Stefanini FR
title	Profile of ocriplasmin and its potential in the treatment of vitreomacular adhesion
title_short	Profile of ocriplasmin and its potential in the treatment of vitreomacular adhesion
title_full	Profile of ocriplasmin and its potential in the treatment of vitreomacular adhesion
title_fullStr	Profile of ocriplasmin and its potential in the treatment of vitreomacular adhesion
title_full_unstemmed	Profile of ocriplasmin and its potential in the treatment of vitreomacular adhesion
title_sort	profile of ocriplasmin and its potential in the treatment of vitreomacular adhesion
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/ad39e17d92fb45198ed107c387ba6ae9
work_keys_str_mv	AT stefaninifr profileofocriplasminanditspotentialinthetreatmentofvitreomacularadhesion AT maiam profileofocriplasminanditspotentialinthetreatmentofvitreomacularadhesion AT falabellap profileofocriplasminanditspotentialinthetreatmentofvitreomacularadhesion AT pfisterm profileofocriplasminanditspotentialinthetreatmentofvitreomacularadhesion AT niemeyerm profileofocriplasminanditspotentialinthetreatmentofvitreomacularadhesion AT kashaniah profileofocriplasminanditspotentialinthetreatmentofvitreomacularadhesion AT humayunms profileofocriplasminanditspotentialinthetreatmentofvitreomacularadhesion AT kossmj profileofocriplasminanditspotentialinthetreatmentofvitreomacularadhesion
_version_	1718399420014264320

Profile of ocriplasmin and its potential in the treatment of vitreomacular adhesion

Ejemplares similares